Tracking of low disease burden in multiple myeloma: Using mass spectrometry assays in peripheral blood.

Jessica R Chapman, Katie L Thoren

Journal: Best practice & research. Clinical haematology 2020;33(1):101142

PMID: 32139008

Full Text on Elsevier Science View on PubMed

Abstract

Efforts over the last 5 years have demonstrated that it is technically feasible to detect low levels of monoclonal proteins in peripheral blood using mass spectrometry. These methods are based on the fact that an M-protein has a specific amino acid sequence, and therefore, a specific mass. This mass can be tracked over time and can serve as a surrogate marker of the presence of clonal plasma cells. This review describes the use of mass spectrometry to detect M-proteins in multiple myeloma to date, identifies the challenges of using this biomarker, and describes potential strategies to overcome these challenges. We discuss the work that must be done for these techniques to be incorporated into clinical practice for tracking of low disease burden in multiple myeloma.

Address: Hematopathology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA. Electronic address: [email protected].; Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 327 East 64th St, New York, NY, 10065, USA. Electronic address: [email protected].

DOI: 10.1016/j.beha.2020.101142

Link outs

Free resources

Medical:

https://medlineplus.gov/multiplemyeloma.html

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Subscription / membership required

Full Text Sources:

MeSH Terms: Biomarkers, Tumor, Gene Expression, Half-Life, Humans, Immunoglobulin A, Immunoglobulin G, Multiple Myeloma, Myeloma Proteins, Neoplasm, Residual, Plasma Cells, Sensitivity and Specificity, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization